Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

CRISPR

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced Short...

CRISPR

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced Short...

CRISPR/Cas9 Genome Editing

CRISPR/Cas9 Genome Editing

The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Homologous Recombination

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...

CRISPR and crRNAs

CRISPR and crRNAs

Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Microneedle technologies in emerging strategies for non-transdermal drug delivery.

International journal of pharmaceutics·2026

Same author

Nanorobotics at a crossroads: an overview of design, propulsion, and applications.

International journal of pharmaceutics·2026

Same author

CRISPR Applications in HIV Management - Prevention, Diagnosis, Monitoring and Treatment.

Current HIV/AIDS reports·2026

Same author

Dual-targeted hyaluronic acid conjugates on lipid nanoparticles improve delivery and efficacy against glioblastoma: The linkage leads the fate.

International journal of biological macromolecules·2025

Same author

Additive manufacturing of microneedles: a quality by design approach to clinical translation.

International journal of pharmaceutics·2025

Same author

Optimizing Pluronic-PEI Nanocarriers for RNAi Delivery in Oral Cancer: From Polymer Synthesis to Functional Screening.

Biomacromolecules·2025

Search research articles

Related Experiment Video

Updated: Jul 16, 2026

Improving CRISPR-Cas9 Screens in CAR T Cells: A Refined Method for Library Preparation

Improving CRISPR-Cas9 Screens in CAR T Cells: A Refined Method for Library Preparation

Published on: January 2, 2026

Decoding and Overcoming Temozolomide Resistance Through CRISPR/Cas Technologies.

Bárbara S Marques^1,2, Maria Mendes^3,4, José Luís Alves^5,6,7

¹Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.

Molecular Diagnosis & Therapy

|July 15, 2026

Summary

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated protein (Cas) technologies are emerging as a dual approach to overcome temozolomide resistance in glioblastoma. These tools help identify resistance mechanisms and develop strategies to restore drug sensitivity.

More Related Videos

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Published on: July 22, 2019

QTL Mapping and CRISPR/Cas9 Editing to Identify a Drug Resistance Gene in Toxoplasma gondii

QTL Mapping and CRISPR/Cas9 Editing to Identify a Drug Resistance Gene in Toxoplasma gondii

Published on: June 22, 2017

Related Experiment Videos

Last Updated: Jul 16, 2026

Improving CRISPR-Cas9 Screens in CAR T Cells: A Refined Method for Library Preparation

Improving CRISPR-Cas9 Screens in CAR T Cells: A Refined Method for Library Preparation

Published on: January 2, 2026

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Published on: July 22, 2019

QTL Mapping and CRISPR/Cas9 Editing to Identify a Drug Resistance Gene in Toxoplasma gondii

QTL Mapping and CRISPR/Cas9 Editing to Identify a Drug Resistance Gene in Toxoplasma gondii

Published on: June 22, 2017

Area of Science:

Oncology
Genetics
Biotechnology

Background:

Glioblastoma (GBM) frequently develops resistance to temozolomide (TMZ), a standard chemotherapy, leading to poor patient outcomes.
Understanding the mechanisms driving this resistance is crucial for developing effective treatment strategies.

Purpose of the Study:

To review the dual role of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated protein (Cas) technologies in addressing TMZ resistance in GBM.
To highlight how CRISPR screens identify resistance drivers and how CRISPR/Cas systems can be used to restore TMZ sensitivity.

Main Methods:

Genome-wide CRISPR screens to identify genetic and epigenetic factors contributing to TMZ resistance.
CRISPR/Cas-based strategies for targeted gene disruption and epigenetic modification (e.g., of MGMT).
Development of CRISPR/Cas-engineered GBM models for therapeutic research.

Main Results:

CRISPR screens revealed DNA damage repair, stress adaptation, stemness, and tumor heterogeneity as key drivers of TMZ resistance.
CRISPR/Cas strategies show potential for restoring TMZ sensitivity by targeting resistance mechanisms, including MGMT.
CRISPR/Cas-engineered models facilitate the study of GBM biology and therapeutic responses.

Conclusions:

CRISPR/Cas technologies offer a powerful approach to dissecting TMZ resistance in GBM.
These technologies can guide the development of rational therapeutic strategies to improve GBM treatment outcomes.
Further refinement of CRISPR/Cas tools holds promise for more effective GBM therapies.